TABLE 1.
Pharmacogenetic actionability among AGHI participants prescribed warfarin overall, stratified by race, and stratified by race and gender
| Gene and variant | Total (n = 89) | Black (n = 18) | White (n = 72) | Black women (n = 15) | White women (n = 30) | Black men (n = 3) | White men (n = 42) |
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| CYP2C9 (*2, *3) and VKORC1 rs9923231 | 30 (33.7%) | 2 (11.1%) | 28 (38.9%) | 2 (13.3%) | 9 (30.0%) | 0 (0.0%) | 19 (45.2%) |
| CYP2C9 a *5, *6, *11 | 2 (2.2%) | 1 (5.6%) | 1 (1.4%) | 1 (6.7%) | 1 (3.3%) | 0 (0.0%) | 0 (0.0%) |
| CYP4F2 rs2108622 | 8 (9.0%) | Not actionable | 8 (11.1%) | Not actionable | 6 (20.0%) | Not actionable | 2 (4.8%) |
| CYP2C rs12777823 | 27 (30.3%) | 12 (66.7%) | Not actionable | 9 (60.0%) | Not actionable | 3 (100%) | Not actionable |
| Overall actionability | 53 (59.6%) | 13 (72.2%) | 33 (45.8%) | 10 (66.7%) | 13 (43.3%) | 3 (100%) | 20 (47.6%) |
Abbreviation: AGHI, Alabama Genomic Health Initiative.
a
Data for CYP2C9*8, the most common CYP2C9 variant in Blacks, was not included on the global screening array.